Innovent starts Phase III of PD-1 inhibitor in squamous NSCLC after Phase Ib readout

Innovent Biologics Inc. (HKSE:1801) reported data from 17 evaluable patients with squamous non-small cell lung cancer (NSCLC) in cohort E of an open-label, Chinese

Read the full 249 word article

User Sign In